Eli Lilly licensed AC Immune's Tau Morphomer small molecule discovery program for Alzheimer's disease and other neurodegenerative diseases. AC Immune received CHF 80M upfront ($80M) plus a CHF 50M equity investment, with up to CHF 1.7B (~$1.8B) in development, regulatory and commercial milestones plus tiered royalties on net sales.
Key facts
AnnouncedJan 07, 2019
Deal value$1.9B
Deal typeLicensing/Option
Therapeutic areaAlzheimer's disease
IndicationsAlzheimer's disease
Key assetsTau Morphomer small molecule discovery program